Evidence map›Paper›PMID 38622136›Full record

ArticleCell death discovery2024

Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma.

Maria R Cavallo, Jacob C Yo, Kayla C Gallant, Camille J Cunanan, Amirali Amirfallah, Marzieh Daniali, Alyssa B Sanders, Andrew E Aplin, Edmund A Pribitkin, Edward J Hartsough

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maria R CavalloDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.ORCID http://orcid.org/0000-0003-2179-6178
Jacob C YoGraduate School of Biomedical Sciences and Professional Studies, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.
Kayla C GallantDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.ORCID http://orcid.org/0009-0002-9940-164X
Camille J CunananDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.ORCID http://orcid.org/0000-0003-0022-6117
Amirali AmirfallahDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.ORCID http://orcid.org/0009-0005-7453-6718
Marzieh DanialiDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.ORCID http://orcid.org/0000-0001-7703-8777
Alyssa B SandersDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA.ORCID http://orcid.org/0009-0009-1839-4793
Andrew E AplinSidney Kimmel Cancer Center, Philadelphia, PA, 19107, USA.ORCID http://orcid.org/0000-0002-2734-3244
Edmund A PribitkinDepartments of Otolargynology-Head & Neck Surgery, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Edward J HartsoughDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, 19102, USA. ejh329@drexel.edu.ORCID http://orcid.org/0000-0002-5109-3978
Drexel University · USThomas Jefferson University · USSidney Kimmel Cancer Center · US

Funding

Request for Supplemental Funds aligned to CA160495R01CA160495 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2012 to 2022
$3.6M
Targeted therapies in mutant BRAF melanomaR01CA182635 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2014 to 2024
$3.4M
Exploiting oxidative stress response in uveal melanoma liver metastasesR01CA282901 · NCI · DREXEL UNIVERSITY · PI Edward Hartsough · 2024 to 2026
$1.4M
The role of CADM1 in malignant melanomaR00CA207855 · NCI · DREXEL UNIVERSITY · PI HARTSOUGH, EDWARD · 2018 to 2020
$701k
The role of CADM1 in malignant melanomaK99CA207855 · NCI · THOMAS JEFFERSON UNIVERSITY · PI HARTSOUGH, EDWARD · 2017 to 2018
$219k
NCI NIH HHS K99 CA207855NCI NIH HHS R00 CA207855NCI NIH HHS R01 CA160495NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA282901
6 · The paper itself

Abstract

Papillary thyroid carcinoma (PTC) is the most frequent form of thyroid cancer. PTC commonly presents with mutations of the serine/threonine kinase BRAF (BRAF

Identifiers

PMID38622136
PMCPMC11018618
OpenAlexW4394819396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.